Adiponectin and Insulin Resistance in Diabetic Nephropathy

Overview

Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB), especially in subjects with type 2 diabetes in different stage of chronic kidney disease (CKD).

Full Title of Study: “Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2007

Interventions

  • Drug: Losartan
    • Angiotensin II Type 1 Receptor Blockers

Clinical Trial Outcome Measures

Primary Measures

  • GFR, HbA1c and the adiponectin concentration
    • Time Frame: 6 month

Participating in This Clinical Trial

Inclusion Criteria

  • Type 2 diabetic nephropathy – CKD at stage 1~4 Exclusion Criteria:

  • Type 1 diabetes or nondiabetic renal disease – An elevated plasma K level.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Health Science Center of Xi’an Jiaotong University
  • Collaborator
    • Shanghai Jiao Tong University School of Medicine
  • Provider of Information About this Clinical Study
    • hui min Jin, shanghai No 3 people’s hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.